Emergence Therapeutics

Duisburg, Germany Founded: 2019 • Age: 7 yrs Acquired By Lilly
Immunotherapeutics for cancer treatment are developed using ATAC technology.
Request Access

About Emergence Therapeutics

Emergence Therapeutics is a company based in Duisburg (Germany) founded in 2019 by Xavier Preville was acquired by Lilly in June 2023.. Emergence Therapeutics has raised $98.2 million across 3 funding rounds from investors including Lilly, Heidelberg Pharma and Orbimed. Emergence Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.

  • Headquarter Duisburg, Germany
  • Founders Xavier Preville
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Legal Name Emergence Therapeutics Ag
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $98.2 M (USD)

    in 3 rounds

  • Latest Funding Round
    $98.2 M (USD), Series A

    Dec 07, 2021

  • Investors
    Lilly

    & 12 more

  • Employee Count
    Employee Count
  • Acquired by
    Lilly

    (Jun 29, 2023)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Emergence Therapeutics
Headcount 1-10
Employee Profiles 10
Board Members and Advisors 12
Employee Profiles
People
Florence Lhospice
Chief Development Officer
People
Carsten Dehning
Chief Financial Officer
People
Romain Lafitte
Associate Director, Finance
People
Xavier Preville
Chief Scientific Officer

Unlock access to complete

Board Members and Advisors
people
Aristotelis Nastos
Deputy Chairman
people
Peter Neubeck
Chairman of the Supervisory Board
people
Ohad Hammer
Supervisory Director
people
Robert Lutz
Scientific Advisor

Unlock access to complete

Funding Insights of Emergence Therapeutics

Emergence Therapeutics has successfully raised a total of $98.2M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $98.2 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series A — $98.2M
  • First Round
  • Investors Count 12
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2021 Amount Series A - Emergence Therapeutics Valuation Pontifax
Nov, 2020 Amount Seed - Emergence Therapeutics Valuation HTGF
Nov, 2019 Amount Seed - Emergence Therapeutics Valuation HTGF
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Emergence Therapeutics

Emergence Therapeutics has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Heidelberg Pharma and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
Founded Year Domain Location
Pontifax Venture Capital is focused on life sciences investments.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Emergence Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Emergence Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Emergence Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Emergence Therapeutics

Emergence Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Cancer therapies are developed using selective pathway inhibitors.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Emergence Therapeutics

Frequently Asked Questions about Emergence Therapeutics

When was Emergence Therapeutics founded?

Emergence Therapeutics was founded in 2019.

Where is Emergence Therapeutics located?

Emergence Therapeutics is headquartered in Duisburg, Germany. It is registered at Duisburg, North Rhine-westphalia, Germany.

Is Emergence Therapeutics a funded company?

Emergence Therapeutics is a funded company, having raised a total of $98.2M across 3 funding rounds to date.

What does Emergence Therapeutics do?

Emergence Therapeutics was founded in 2019 and is based in Duisburg, Germany. Novel antibody-drug conjugate immunotherapeutics are developed by the company to address various cancers. Proprietary ATAC technology is utilized to target Nectin-4, a protein expressed in multiple tumor types. Operations focus on advancing these therapies through preclinical and clinical stages within the biotechnology sector.

Who are the top competitors of Emergence Therapeutics?

Emergence Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.

Who are Emergence Therapeutics's investors?

Emergence Therapeutics has 13 investors. Key investors include Lilly, Heidelberg Pharma, Orbimed, NRW.Bank, and Bpifrance.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available